Cargando…

Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds

The pivotal role of cancer stem cells (CSCs) in the initiation and progression of malignancies has been rigorously validated, and the specific methods for identifying and isolating the CSCs from the parental cancer population have also been rapidly developed in recent years. This review aims to prov...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ming, Tan, Hor Yue, Li, Sha, Cheung, Fan, Wang, Ning, Nagamatsu, Tadashi, Feng, Yibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926427/
https://www.ncbi.nlm.nih.gov/pubmed/27338343
http://dx.doi.org/10.3390/ijms17060893
_version_ 1782440110518697984
author Hong, Ming
Tan, Hor Yue
Li, Sha
Cheung, Fan
Wang, Ning
Nagamatsu, Tadashi
Feng, Yibin
author_facet Hong, Ming
Tan, Hor Yue
Li, Sha
Cheung, Fan
Wang, Ning
Nagamatsu, Tadashi
Feng, Yibin
author_sort Hong, Ming
collection PubMed
description The pivotal role of cancer stem cells (CSCs) in the initiation and progression of malignancies has been rigorously validated, and the specific methods for identifying and isolating the CSCs from the parental cancer population have also been rapidly developed in recent years. This review aims to provide an overview of recent research progress of Chinese medicines (CMs) and their active compounds in inhibiting tumor progression by targeting CSCs. A great deal of CMs and their active compounds, such as Antrodia camphorate, berberine, resveratrol, and curcumin have been shown to regress CSCs, in terms of reversing drug resistance, inducing cell death and inhibiting cell proliferation as well as metastasis. Furthermore, one of the active compounds in coptis, berbamine may inhibit tumor progression by modulating microRNAs to regulate CSCs. The underlying molecular mechanisms and related signaling pathways involved in these processes were also discussed and concluded in this paper. Overall, the use of CMs and their active compounds may be a promising therapeutic strategy to eradicate cancer by targeting CSCs. However, further studies are needed to clarify the potential of clinical application of CMs and their active compounds as complementary and alternative therapy in this field.
format Online
Article
Text
id pubmed-4926427
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-49264272016-07-06 Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds Hong, Ming Tan, Hor Yue Li, Sha Cheung, Fan Wang, Ning Nagamatsu, Tadashi Feng, Yibin Int J Mol Sci Review The pivotal role of cancer stem cells (CSCs) in the initiation and progression of malignancies has been rigorously validated, and the specific methods for identifying and isolating the CSCs from the parental cancer population have also been rapidly developed in recent years. This review aims to provide an overview of recent research progress of Chinese medicines (CMs) and their active compounds in inhibiting tumor progression by targeting CSCs. A great deal of CMs and their active compounds, such as Antrodia camphorate, berberine, resveratrol, and curcumin have been shown to regress CSCs, in terms of reversing drug resistance, inducing cell death and inhibiting cell proliferation as well as metastasis. Furthermore, one of the active compounds in coptis, berbamine may inhibit tumor progression by modulating microRNAs to regulate CSCs. The underlying molecular mechanisms and related signaling pathways involved in these processes were also discussed and concluded in this paper. Overall, the use of CMs and their active compounds may be a promising therapeutic strategy to eradicate cancer by targeting CSCs. However, further studies are needed to clarify the potential of clinical application of CMs and their active compounds as complementary and alternative therapy in this field. MDPI 2016-06-07 /pmc/articles/PMC4926427/ /pubmed/27338343 http://dx.doi.org/10.3390/ijms17060893 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hong, Ming
Tan, Hor Yue
Li, Sha
Cheung, Fan
Wang, Ning
Nagamatsu, Tadashi
Feng, Yibin
Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds
title Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds
title_full Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds
title_fullStr Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds
title_full_unstemmed Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds
title_short Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds
title_sort cancer stem cells: the potential targets of chinese medicines and their active compounds
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926427/
https://www.ncbi.nlm.nih.gov/pubmed/27338343
http://dx.doi.org/10.3390/ijms17060893
work_keys_str_mv AT hongming cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds
AT tanhoryue cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds
AT lisha cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds
AT cheungfan cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds
AT wangning cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds
AT nagamatsutadashi cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds
AT fengyibin cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds